Relaxin Prevents Cardiac Fibroblast-Myofibroblast Transition via Notch-1-Mediated Inhibition of TGF-β/Smad3 Signaling

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Sassoli, Chiara ^a   Chellini, Flaminia ^a   Pini, Alessandro ^a   Tani, Alessia ^a   Nistri, Silvia ^a   Nosi, Daniele ^a   Zecchi Orlandini, Sandra ^a   Bani, Daniele ^a   Formigli, Lucia ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; GELATINASE A; GELATINASE B; JAGGED1; NOTCH1 RECEPTOR; RELAXIN; SMAD3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; FIBROBLAST; MOUSE; MYOFIBROBLAST; NEWBORN; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STROMA CELL; UPREGULATION;

ACTINS; ANIMALS; ANIMALS, NEWBORN; COLLAGEN TYPE I; CYTOSKELETON; DOWN-REGULATION; HUMANS; MICE; MYOCARDIUM; MYOFIBROBLASTS; NIH 3T3 CELLS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NOTCH; RECEPTORS, PEPTIDE; RELAXIN; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84877989995     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063896     Document Type: Article

References (55)

1. Samuel CS, Lekgabe ED, Mookerjee I, (2007) The effects of relaxin on extracellular matrix remodeling in health and fibrotic disease. Adv Exp Med Biol 612: 88-103.
2. Samuel CS, (2005) Relaxin: antifibrotic properties and effects in models of disease. Clin Med Res 3: 241-249.
3. Hisaw FL, (1926) Experimental relaxation of the pubic ligament of the guinea pig. Proc Soc Exp Biol Med 23: 661-663.
4. Dschietzig T, Bartsch C, Baumann G, Stangl K, (2006) Relaxin-a pleiotropic hormone and its emerging role for experimental and clinical therapeutics. Pharmacol Ther 112: 38-56.
5. Du XJ, Bathgate RA, Samuel CS, Dart AM, Summers RJ, (2010) Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol 7: 48-58.
6. Nistri S, Bigazzi M, Bani D, (2007) Relaxin as a cardiovascular hormone. Physiology, pathophysiology and therapeutic promises. Cardiovasc Hematol Agents Med Chem (CHA-MC) 5: 101-108.
7. Pini A, Samuel CS, Shemesh R, Bani D, (2012) New views on relaxin and relaxin-receptor agonists for the treatment of lung fibrosis: evidences from in vivo models. AoRM (Ann Respir Med) 3(2): 65-71.
8. Du XJ, Samuel CS, Gao XM, Zhao L, Parry LJ, et al. (2003) Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: a gender-specific phenotype. Cardiovasc Res 57: 395-404.
9. Huang X, Gai Y, Yang N, Lu B, Samuel CS, et al. (2011) Relaxin regulates myofibroblast contractility and protects against lung fibrosis. Am J Pathol 179: 2751-2765.
10. Samuel CS, Zhao C, Bathgate RA, Bond CP, Burton MD, et al. (2003) Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis. FASEB J 17: 121-123.
11. Samuel CS, Zhao C, Bond CP, Hewitson TD, Amento EP, et al. (2004) Relaxin-1-deficient mice develop an age-related progression of renal fibrosis. Kidney Int 65: 2054-2064.
12. Pini A, Shemesh R, Samuel CS, Bathgate RA, Zauberman A, et al. (2010) Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity. J Pharmacol Exp Ther 335: 589-599.
13. Royce SG, Cheng V, Samuel CS, Tang ML, (2012) The regulation of fibrosis in airway remodeling in asthma. Mol Cell Endocrinol 351: 167-175.
14. Mu X, Urso ML, Murray K, Fu F, Li Y, (2010) Relaxin regulates MMP expression and promotes satellite cell mobilization during muscle healing in both young and aged mice. Am J Pathol 177: 2399-2410.
15. Negishi S, Li Y, Usas A, Fu FH, Huard J, (2005) The effect of relaxin treatment on skeletal muscle injuries. Am J Sports Med 33: 1816-1824.
16. Mookerjee I, Hewitson TD, Halls ML, Summers RJ, Mathai ML, et al. (2009) Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J 23: 1219-1229.
17. Samuel CS, Cendrawan S, Gao XM, Ming Z, Zhao C, et al. (2011) Relaxin remodels fibrotic healing following myocardial infarction. Lab Invest 91: 675-690.
18. Samuel CS, Mookerjee I, Halls ML, Summers RJ, Chew E, et al. (2009) Investigations into the inhibitory effects of relaxin on renal myofibroblast differentiation. Ann N Y Acad Sci 1160: 294-299.
19. Samuel CS, Unemori EN, Mookerjee I, Bathgate RA, Layfield SL, et al. (2004) Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 145: 4125-4133.
20. Bani D, Bigazzi M, (2011) Relaxin as a cardiovascular drug: a promise kept. Curr Drug Saf 6: 324-328.
21. Bani D, Yue SK, Bigazzi M, (2009) Clinical profile of relaxin, a possible new drug for human use. Curr Drug Saf 4: 238-249.
22. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G,et al. for the RELAXin in Acute Heart Failure (RELAX-AHF) Investigators (2012) Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet doi:10.1016/S0140-6736 (12)61855-8.
23. Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, et al. (2009) Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373: 1429-1439.
24. Chillakuri CR, Sheppard D, Lea SM, Handford PA, (2012) Notch receptor-ligand binding and activation: insights from molecular studies. Semin Cell Dev Biol 23: 421-428.
25. Fan YH, Dong H, Pan Q, Cao YJ, Li H, et al. (2011) Notch signaling may negatively regulate neonatal rat cardiac fibroblast-myofibroblast transformation. Physiol Res 60: 739-748.
26. Kennard S, Liu H, Lilly B, (2008) Transforming growth factor-beta (TGF- 1) down-regulates Notch-3 in fibroblasts to promote smooth muscle gene expression. J Biol Chem 283: 1324-1333.
27. Liu T, Hu B, Choi YY, Chung M, Ullenbruch M, et al. (2009) Notch1 signaling in FIZZ1 induction of myofibroblast differentiation. Am J Pathol 174: 1745-1755.
28. Mann J, Oakley F, Akiboye F, Elsharkawy A, Thorne AW, et al. (2007) Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis. Cell Death Differ 14: 275-285.
29. Su Y, Büchler P, Gazdhar A, Giese N, Reber HA, et al. (2006) Pancreatic regeneration in chronic pancreatitis requires activation of the Notch signaling pathway. J Gastrointest Surg 10: 1230-1241.
30. Barter MJ, Pybus L, Litherland GJ, Rowan AD, Clark IM, et al. (2010) HDAC-mediated control of ERK- and PI3K-dependent TGF-β-induced extracellular matrix-regulating genes. Matrix Biol 29: 602-612.
31. Solomon E, Li H, Duhachek Muggy S, Syta E, Zolkiewska A, (2010) The role of SnoN in transforming growth factor beta1-induced expression of metalloprotease-disintegrin ADAM12. J Biol Chem 285: 21969-21977.
32. Dreymueller D, Pruessmeyer J, Groth E, Ludwig A, (2012) The role of ADAM-mediated shedding in vascular biology. Eur J Cell Biol 91: 472-485.
33. Groot AJ, Vooijs MA, (2012) The role of Adams in Notch signaling. Adv Exp Med Biol 727: 15-36.
34. Formigli L, Francini F, Nistri S, Margheri M, Luciani G, et al. (2009) Skeletal myoblasts overexpressing relaxin improve differentiation and communication of primary murine cardiomyocyte cell cultures. J Mol Cell Cardiol 47: 335-345.
35. Nistri S, Pini A, Sassoli C, Squecco R, Francini F, et al. (2012) Relaxin promotes growth and maturation of mouse neonatal cardiomyocytes in vitro. Clues for cardiac regeneration. J Cell Mol Med 16: 507-519.
36. Sassoli C, Pini A, Mazzanti B, Quercioli F, Nistri S, et al. (2011) Mesenchymal stromal cells affect cardiomyocyte growth through juxtacrine Notch-1/Jagged-1 signaling and paracrine mechanisms: clues for cardiac regeneration. J Mol Cell Cardiol. 51: 399-408.
37. Sassoli C, Pini A, Chellini F, Mazzanti B, Nistri S, et al. (2012) Bone marrow mesenchymal stromal cells stimulate skeletal myoblast proliferation through the paracrine release of VEGF. PLoS One 7(7): e37512 doi:10.1371/journal.pone.0037512.
38. Lu KV, Jong KA, Rajasekaran AK, Cloughesy TF, Mischel PS, (2004) Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Lab Invest 84: 8-20.
39. Fan D, Takawale A, Lee J, Kassiri Z, (2012) Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair. 5: 15 doi:10.1186/1755-1536-5-15.
40. Kolonin MG, Evans KW, Mani SA, Gomer RH, (2012) Alternative origins of stroma in normal organs and disease. Stem Cell Res 8: 312-323.
41. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, et al. (2005) Increased expression of integrin alpha(v)beta3 contributes to the establishment of autocrine TGF-beta signaling in scleroderma fibroblasts. J Immunol 175: 7708-7718.
42. Visse R, Nagase H, (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827-839.
43. Barnes BR, Szelenyi ER, Warren GL, Urso ML, (2009) Alterations in mRNA and protein levels of metalloproteinases-2,-9, and-14 and tissue inhibitor of metalloproteinase-2 responses to traumatic skeletal muscle injury. Am J Physiol Cell Physiol 297: C1501-1508.
44. Ahmad N, Wang W, Nair R, Kapila S, (2012) Relaxin induces matrix-metalloproteinases-9 and-13 via RXFP1: induction of MMP-9 involves the PI3K, ERK, Akt and PKC-ζ pathways. Mol Cell Endocrinol 363: 46-61.
45. Samuel CS, Lin F, Hossain MA, Zhao C, Ferraro T, et al. (2007) Improved chemical synthesis and demonstration of the relaxin receptor binding affinity and biological activity of mouse relaxin. Biochemistry 46: 5374-5381.
46. Feng XH, Derynck R, (2005) Specificity and versatility in TGF-beta signaling through Smads. Annu Rev Cell Dev Biol 21: 659-693.
47. Samarakoon R, Overstreet JM, Higgins PJ, (2013) TGF-β signaling in tissue fibrosis: Redox controls, target genes and therapeutic opportunities. Cell Signal 25: 264-268.
48. Chow BS, Chew EG, Zhao C, Bathgate RA, Hewitson TD, et al. (2012) Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS. PLoS One. 7(8): e42714 doi:10.1371/journal.pone.0042714.
49. Nemir M, Metrich M, Plaisance I, Lepore M, Cruchet S, et al. (2012) The Notch pathway controls fibrotic and regenerative repair in the adult heart. Eur Heart J doi: 10.1093/eurheartj/ehs269.
50. Blokzijl A, Dahlqvist C, Reissmann E, Falk A, Moliner A, et al. (2003) Cross-talk between the Notch and TGF-beta signaling pathways mediated by interaction of the Notch intracellular domain with Smad3. J Cell Biol 163: 723-728.
51. Dahlqvist C, Blokzijl A, Chapman G, Falk A, Dannaeus K, et al. (2003) Functional Notch signaling is required for BMP4-induced inhibition of myogenic differentiation. Development. 130: 6089-6099.
52. Zavadil J, Cermak L, Soto-Nieves N, Böttinger EP, (2004) Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J 23: 1155-1165.
53. Hurlbut GD, Kankel MW, Lake RJ, Artavanis-Tsakonas S, (2007) Crossing paths with Notch in the hyper-network. Curr Opin Cell Biol 19: 166-175.
54. Baccari MC, Bani D, (2008) Relaxin and nitric oxide signalling. Curr Protein Pept Sci 9: 638-645.
55. Ishimura N, Bronk SF, Gores GJ, (2005) Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology 128: 1354-1368.